# Alector (ALEC) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ALEC
## Company Profile
- Ticker: ALEC
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology
## Stock Data
- Close: 2.09 USD
- Market cap: 216499114.65 USD
- Last updated: 2026-08-11
## Business Overview
### Neurodegeneration and Immunology
Alector develops therapies for neurodegenerative diseases using insights from human genetics, immunology and neuroscience. Its programs seek to remove toxic proteins, replace deficient proteins and restore immune function in the brain.
### Alector Brain Carrier
The Alector Brain Carrier platform is designed to transport therapeutic payloads across the blood-brain barrier. It is being applied to antibodies, enzyme-replacement therapies and siRNA molecules.
### AL037 and AL137
AL037 and AL137 are brain-carrier-enabled antibodies targeting a toxic pyroglutamate amyloid-beta epitope in Alzheimer's disease. The candidates share the same antibody but use carrier domains with different binding properties.
### AL050
AL050 is an ABC-enabled GCase enzyme-replacement therapy intended to restore lysosomal function in Parkinson's disease while improving delivery into the brain.
### Tau siRNA Programs
AL064 and its optimized successor AL164 use the brain carrier to deliver tau-directed siRNA for Alzheimer's disease and other tauopathies. Additional siRNA research targets alpha-synuclein and NLRP3.
## Why The Stock Is Moving

As of Aug 11, 2026, ALEC closed up 23.7% at $2.09. No new same-company headline was identified in the current news window.

## Future Catalysts

- IND submission for AL037/AL137 in the first quarter of 2027.

## Recent News
- 2026-08-06 20:05 EST — [Alector Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ALEC/alector-reports-second-quarter-2026-financial-results-and-provides-business-upda-d57d0201) — Source: Alector
- 2026-05-07 20:05 EST — [Alector Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ALEC/alector-reports-first-quarter-2026-financial-results-and-provides-business-updat-145e9f5a) — Source: Alector
- 2026-04-29 20:05 EST — [Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis](https://biopharmsignal.com/news/ALEC/alector-to-discontinue-phase-2-progress-ad-trial-of-nivisnebart-al101-gsk4527226-1b3ecd87) — Source: Alector
- 2026-02-25 21:05 EST — [Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ALEC/alector-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-71948925) — Source: Alector
- 2026-02-24 13:00 EST — [Alector to Participate in the TD Cowen 46th Annual Health Care Conference](https://biopharmsignal.com/news/ALEC/alector-to-participate-in-the-td-cowen-46th-annual-health-care-conference-37db60ef) — Source: Alector